发明授权
US6068840A Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing
CDRs or the variable region from the mouse monoclonal antibody, WS-4
失效
含有CDR或来自小鼠单克隆抗体WS-4的可变区的重组CDR-移植和嵌合抗IL-8抗体
- 专利标题： Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing CDRs or the variable region from the mouse monoclonal antibody, WS-4
- 专利标题（中）： 含有CDR或来自小鼠单克隆抗体WS-4的可变区的重组CDR-移植和嵌合抗IL-8抗体
-
申请号： US902201申请日： 1997-07-29
-
公开(公告)号： US6068840A公开(公告)日： 2000-05-30
- 发明人: Kouji Matsushima , Yoshihiro Matsumoto , Yoshiki Yamada , Koh Sato , Masayuki Tsuchiya , Tatsumi Yamazaki
- 申请人： Kouji Matsushima , Yoshihiro Matsumoto , Yoshiki Yamada , Koh Sato , Masayuki Tsuchiya , Tatsumi Yamazaki
- 申请人地址： JPX Tokyo
- 专利权人： Chugai Pharmaceutical Co., Ltd.
- 当前专利权人： Chugai Pharmaceutical Co., Ltd.
- 当前专利权人地址： JPX Tokyo
- 优先权： JPX6-161481 19940713
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61P29/00 ; A61P37/02 ; C07K16/24 ; C12N15/13 ; C12P21/08
摘要：
Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.
公开/授权文献
信息查询
